Indirect Comparison of the Relative Effectiveness of Faricimab vs Aflibercept 8 mg in DME and nAMD

Related

• 

  PRISM Phase 2b Clinical Trial Evaluating Intravitreal 4D-150 in Adults With Neovascular Age-Related Macular Degeneration: 52-Week Results

  John A. Wells, MD, FACS

  Annual Meeting Talks

  2025

• 

  Expert Panel: Faricimab and Aflibercept 8 mg in AMD

  John T. Thompson, MD

  Andrew A. Moshfeghi, MD, MBA, FASRS

  Manjot K Gill, MD, FASRS

  Christina Y Weng, MD, MBA, FASRS

  Ferhina S Ali, MD, MPH

  Ian Pearce, MB ChB BSc FRCOPHTH

  Annual Meeting Talks

  2024

• 

  Update on Faricimab for DME: New Clinical Features of Eyes in the RHONE-X Long-Term Extension Study

  Veeral S. Sheth, MD, MBA, FASRS, FACS

  Annual Meeting Talks

  2025